Specialty Pharmaceutical Hub Services News Roundup: November 2023

COPILOT Provider Support Services, a leading HUB, now offers an updated version of AUTOPILOT – the company’s proprietary electronic benefits verification (eBV) and electronic prior authorization (ePA) platform. The innovative solution empowers patient support services protocols and complies with the Centers for Medicare and Medicaid Services (CMS) industry policy. COPILOT offers technology enablement solutions to practice management and provider staff that deliver highly accurate and timely benefits investigations for specialty medications, medical devices, and laboratory testing. The real-time, easily accessible, web-based portal securely displays accurate data that brings value to provider offices and pharma clients to best manage each patient’s journey. With an experienced team and longevity in HUB and reimbursement services, we provide guidance in market access and drive high satisfaction for our clients. COPILOT is headquartered in Maitland, FL, and is a portfolio company of QHP Capital LP.


EVERSANA, a leading provider of commercial services to the global life sciences industry, has selected Adobe Firefly for Enterprise to transform its content supply chains with the power of generative AI. EVERSANA and its agency team at EVERSANA INTOUCH™ will have full access to the transformative capabilities of Adobe Firefly generative AI across Adobe Creative Cloud applications. Firefly for Enterprise will integrate seamlessly into EVERSANA INTOUCH’s proprietary content supply chain engine and processes to accelerate content creation, approval, and dissemination in the highly regulated and complex life sciences sector. The technology, combined with the skill of life science marketing strategists and creative development teams, will streamline content creation, further enabling the timely delivery of personalized content that is designed to be safe for commercial use, to engage with multiple healthcare audiences.


Building on a promise to “pharmatize” artificial intelligence (AI) across the life sciences sector, EVERSANA®, a leading provider of commercial services to the global life sciences industry, announced the first of several new generative AI-based innovations on Amazon Web Services (AWS) to drive greater efficiency and business value for companies and ultimately improved patient outcomes. The first solution, developed by EVERSANA leveraging AWS and AWS Partner TensorIoT, addresses a time-consuming and error-prone process in the industry – medical and regulatory content approvals.   


Fishawack Health recently announced that it is unifying under the new name and brand, Avalere Health. Avalere Health is purposefully built to be the leading, global commercialization partner for changemaking healthcare companies looking to maximize the value of their portfolios while connecting patients to life-changing health solutions. Since its inception in 2001, the company has successfully acquired and integrated 19 best-in-class healthcare agencies and consultancies across North America, Europe and the Asia-Pacific region.


Nordic Capital has signed an agreement to acquire a majority share in IntegriChain, a leading provider of pharmaceutical technology, data, consulting, and outsourcing solutions designed to improve how life sciences products reach customers. IntegriChain delivers pharma’s only fully integrated platform for commercialization and market access, helping manufacturers bring their science to market while ensuring patients have affordable, timely, and sustainable access to therapy. Nordic Capital is acquiring the majority stake from Accel-KKR, a global software private equity firm, which first invested in IntegriChain in 2016. IntegriChain’s integrated ICyte Platform helps connect the commercial, financial, and operational dimensions of drug access and profitability. ICyte enables pharmaceutical innovators to achieve better commercial outcomes by digitalizing daily and recurring business activities and integrating data and operations across contracting, pricing, channel and distribution, and gross-to-net.


OptimizeRx Corp., a the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended September 30, 2023. Quarterly comparisons are to the same year-ago period.

  • Revenue in the third quarter of 2023 increased 8% to $16.3 million, as compared to $15.1 millionin the same year ago period.
  • Gross profit in the third quarter of 2023 increased 4% year-over-year to $9.8 million, from $9.4 millionduring the third quarter of 2022.
  • GAAP net loss totaled $(2.9) millionor $(0.17) per basic and diluted shares outstanding in the third quarter, as compared to $(3.5) million or $(0.19) during the third quarter of 2022.
  • Non-GAAP net income in the third quarter totaled $1.6 millionor $0.09 per fully diluted shares outstanding, as compared to $1.3 million or $0.07 per fully diluted shares outstanding during the third quarter of 2022.




Takeaway: AMI’s annual Specialty Hub Service Providers Report provides comprehensive business intelligence on more than 70 companies